![]() |
|
|
Vol. 62, Issue 1, 7-14, July 2002
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan (Y.K., N.O., A.S., T.S., S.T., T.Y.); and Department of Pharmacology and Toxicology, School of Medicine, Kyorin University, Tokyo Japan (T.S., H.E.)
| |
Abstract |
|---|
|
|
|---|
We isolated cDNA encoding a multispecific organic anion
transporter 2 (OAT2) from the mouse kidney cDNA library. Isolated mouse
OAT2 (mOAT2) consisted of 1623 base pairs that encoded a 540-amino acid
residue protein with 12 putative membrane-spanning domains, and the
amino acid sequence was 87% identical to that of rat OAT2 (rOAT2). The
gene coding for mOAT2, Slc22a7, is found on chromosome
17C. Northern blot analysis revealed that the mOAT2 mRNA is abundantly
expressed in the male mouse kidney, whereas it was predominantly
expressed in both the liver and kidney of female mice. When expressed
in Xenopus laevis oocytes, mOAT2 mediated the high
affinity transport of glutarate (Km = 15.8 ± 3.2 µM) and prostaglandin E2
(Km = 5.2 ± 0.5 nM) in a
sodium-independent manner. mOAT2-expressing oocytes also mediated the
uptake of
-ketoglutarate, glutarate, prostaglandin E2,
p-aminohippuric acid, methotrexate, ochratoxin A,
valproate, and allopurinol. However, we did not observe mOAT2-mediated
uptake of salicylate. A wide range of structurally unrelated organic
anions inhibited mOAT2-mediated glutarate uptake especially
erythromycin, a potent inhibitor. These results indicate that isolated
mOAT2 is a multispecific organic anion transporter having some
differences in substrate specificity compared with rOAT2. In addition,
we found that there exists a sex- and species-related differential gene
expression of the OAT2 isoform.
| |
Introduction |
|---|
|
|
|---|
Organic
anion transporters play central roles in the elimination of a wide
range of endogenous and exogenous anionic compounds including drugs,
environmental toxicants, and their metabolites. Current extensive
molecular studies have identified several families of multispecific
organic anion transporters that are involved in the elimination of
various organic anions (Moller and Sheikh, 1983
; Boyer et al., 1992
;
Pritchard and Miller, 1993
; Ullrich and Rumrich, 1993
; Petzinger, 1994
;
Meier, 1995
; Muller and Jansen, 1997
; Ullrich, 1997
). In the liver and
kidney, water-soluble metabolites and organic anions are actively
eliminated from the body via transporters across their basolateral
and/or luminal membranes (Moller and Sheikh, 1983
; Boyer et al., 1992
;
Pritchard and Miller, 1993
; Ullrich and Rumrich, 1993
; Petzinger, 1994
;
Meier, 1995
; Bossuyt et al., 1996
; Muller and Jansen, 1997
; Ullrich,
1997
). The proximal tubular cells of the kidney take up organic anions
from the blood stream via multispecific organic anion transport
pathway(s) in the basolateral membranes (Moller and Sheikh, 1983
;
Ullrich and Rumrich, 1993
; Pritchard and Miller, 1993
; Ullrich, 1997
).
The liver is a prime metabolic organ and takes up various organic anions from the blood stream via various transporters located in the
sinusoidal membrane (Petzinger, 1994
; Meier, 1995
; Muller and Jansen,
1997
). Thus, the liver and the kidney play an important role in the
elimination and excretion of organic compounds into urine and the gut.
Recently, organic anion transporter 1 (OAT1) belonging to the subgroup
one of the solute carrier superfamily 22A has been isolated and
determined to be located in the basolateral membrane in renal proximal
tubules (Sekine et al., 1997
; Sweet et al., 1997
). OAT1 has a broad
substrate specificity and interacts with a wide range of organic anions
such as p-aminohippuric acid (PAH), dicarboxylates, cyclic
nucleotides, prostaglandin E2
(PGE2) (Sekine et al., 1997
; Sweet et al., 1997
;
Apiwattanakul et al., 1999
). Subsequently, OAT1 orthologs have been
isolated from humans and mice (Lopez-Nieto et al., 1997
; Hosoyamada et
al., 1999
; Kuze et al., 1999
; Lu et al., 1999
; Race et al., 1999
). So
far, four additional members belonging to the organic anion transporter family, OAT2 (Simonson et al., 1994
; Sekine et al., 1998
), OAT3 (Kusuhara et al., 1999
; Race et al., 1999
; Cha et al., 2001
), OAT4 (Cha
et al., 2000
), and OAT5 (Sun et al., 2001
), have been cloned and
identified. Among these OAT homologs, rOAT2 is identical to the
membrane protein previously called the novel liver-specific transport
protein (NLT) (Simonson et al., 1994
). NLT was initially isolated from
a liver cDNA library using a monoclonal antibody raised against the
glucagon receptor; rOAT2 was 42% identical to rat OAT1 (rOAT1)
(Simonson et al., 1994
; Sekine et al., 1998
). We have demonstrated that
rOAT2 mediates the transport of PGE2, methotrexate (MTX), acetylsalicylate, PAH, and
-ketoglutarate in a
sodium-independent manner (Sekine et al., 1998
). Although several OAT
isoforms have been isolated to date, information of the function of
each isoform is still not sufficient. Moreover, the functional property
of mouse OAT homologs is limited despite the fact that mouse OAT1
(mOAT1) (NKT) and mouse OAT3 (mOAT3) (Roct) isoforms have been isolated
(Lopez-Nieto et al., 1997
; Brady et al., 1999
; Kuze et al., 1999
).
Among the OAT isoforms, only OAT2 is predominantly expressed in the
liver, and this isoform is considered one of the key molecules in
hepatic handling of organic anions.
Here, we describe the molecular cloning and functional characterization of mOAT2 from a mouse kidney cDNA library. Our results indicate that mOAT2 is a multispecific organic anion transporter with some differences in substrate specificity compared with rOAT2. Furthermore, the distribution of OAT2 shows sex- and species-related differences.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
[14C]glutarate (2.035 GBq/mmol),
-ketoglutarate (2.01 GBq/mmol),
[3H]MTX (555 GBq/mmol),
[3H]PGE2 (7.429 TBq/mmol), [14C]salicylate (2.01 GBq/mmol) and
[3H]valproate (2.019 GBq/mmol) were purchased
from PerkinElmer Life Sciences (Boston, MA).
[14C]PAH (1.50 GBq/mmol),
[14C]allopurinol (51 GBq/mmol), and
[3H]OTA (547.6 GBq/mmol) were purchased from
Moravek Biochemicals (Brea, CA). Deoxycytidine
[5'-
-32P]triphosphate (dCTP) (111 TBq/mmol)
was obtained from Muromachi Yakuhin Kaisha, LTD (Tokyo, Japan). All
other chemicals not listed here were of the highest grade commercially available.
Construction of cDNA Library and Isolation of mOAT2.
A
nondirectional cDNA library for screening was prepared from mouse
kidney poly(A)+ RNA using Superscript Choice
System (Invitrogen, Carlsbad, CA) and was ligated into a phage
vector
ZipLox EcoRI arms (Invitrogen). The library was
screened by homology using full-length rOAT2 cDNA labeled with
[
-32P]dCTP by random priming (T7Quick Prime
Kit; Amersham Pharmacia Biotech, Uppsala, Sweden) as a probe (Feinberg
and Vogelstein, 1983
). Replicated filters of the phage library were
hybridized overnight in a hybridization solution [50% formamide, 5×
standard saline citrate (SSC), 3× Denhardt's solution, 0.2% SDS,
10% dextran sulfate, 0.3 µg/ml denatured salmon sperm DNA, 2.5 mM
sodium pyrophosphate, 25 mM MES, 0.03% Antifoam A, pH 6.5] at 37°C
overnight. The filters were finally washed in 0.1× SSC and 0.1% SDS
at 37°C. cDNA inserts in positive
ZipLox phage were recovered in
plasmid pZL1 vector by in vitro excision.
Sequence Determination of mOAT2. Double-stranded cDNA of isolated clones were sequenced in both directions. Deleted clones obtained by a KiloSequence deletion kit (Takara, Tokyo, Japan) and specially synthesized oligonucleotide primers were used for sequencing of mOAT2 cDNA, which was sequenced by the dye terminator method using a dye primer cycle sequencing kit (Applied Biosystems, Foster City, CA) and automated Applied Biosystems 310 DNA sequencer. The sequence was assembled and analyzed using DNASIS-Mac, version 3.6 (Hitachi Software Engineering, Yokohama, Kanagawa, Japan).
Total RNA Isolation.
Total RNA was isolated from various
tissues using the acid guanidinium thiocyanate (GTC)-phenol-chloroform
extraction method as described by Chomczynski and Sacchi (1987)
. The
tissue was homogenized in GTC solution (4.0 M GTC containing 25 mM
sodium citrate, pH 7.0, 0.5% sarkosyl, and 0.1 M 2-mercaptoethanol; 10 ml of GTC solution/100 mg of liver tissue). The RNA was extracted twice
into phenol and chloroform (1 volume of phenol/0.2 volumes of
chloroform/1 volume of GTC solution) and precipitated with isopropanol
at room temperature. The pellet was dissolved in 0.3 ml of GTC solution
and precipitated with isopropanol at
20°C. The resulting RNA pellet
was washed with ice-cold 80% ethanol and dissolved in an appropriate
volume of diethylpyrocarbonate-treated water. The RNA yield, purity,
and integrity were determined by the 260 nm/280 nm absorbance ratio
(>1.6) and checked with 1.0% agarose/formamide gel.
Northern Blot Analysis.
Two micrograms of
poly(A)+ RNA prepared from various mouse tissues
were loaded onto 1% agarose/formaldehyde gel. For the study of the
sex-related differential gene expression, 20 µg of total RNA obtained
from the liver and kidney was loaded onto 1.0% agarose/formaldehyde gel. After electrophoresis, the nucleic acids were transferred onto a
nylon membrane (Hybond N+; Amersham Biosciences, Uppsala, Sweden). The
filter was hybridized at 42°C overnight in a hybridization solution
(50% formamide) with a full-length cDNA of mOAT2 or
-actin, which
were randomly labeled with [32P]dCTP. The
filter was finally washed in 0.1× SSC/0.1% SDS at 42°C.
Chromosomal Slide Preparation.
Lymphocytes were isolated
from mouse spleen and cultured at 37°C in an RPMI 1640 medium
supplemented with 15% fetal calf serum, 3 µg/ml concanavalin A, 10 µg/ml lipopolysaccharide and 5 × 10
5 M
mercaptoethanol. After 44 h, the cultured lymphocytes were treated
with 0.18 mg/ml bromodeoxyuridine for an additional 14 h. The
synchronized cells were washed and recultured at 37°C for 4 h in
-minimal essential minimum with thymidine (2.5 µg/ml). Chromosome
slides were made by the conventional methods used for human chromosome
preparation (hypotonic treatment, fixation, and air dry).
Probe Labeling and Fluorescent in Situ Hybridization.
The
mOAT2 DNA probe was biotinylated with dATP using a Invitrogen
BioNick labeling kit (15°C, 1 h) (Heng et al., 1992
). The procedure for fluorescent in situ hybridization (FISH) detection was
performed according to Heng et al. (1992)
and Heng and Tsui (1993)
.
Briefly, slides were heated at 55°C for 1 h. After RNase A
treatment, the slides were denatured in 70% formamide in 2× SSC for 2 min at 70°C followed by dehydration with ethanol. Probes were
denatured at 75°C for 5 min in a hybridization mix consisting of 50%
formamide and 10% dextran sulfate and prehybridized for 15 min at
37°C. Probes were added to the denatured samples on the slides. After
overnight hybridization, slides were amplified by the method of Heng et
al. (1992)
. FISH signals and the 4,6-diamino-2-phenylindole (DAPI)
banding pattern were recorded separately by taking photographs, and the
assignment of the FISH mapping data with chromosomal bands was achieved
by superimposing FISH signals with DAPI-banded chromosomes (Heng and
Tsui, 1993
).
Xenopus Laevis Oocyte Preparation, cRNA Synthesis,
and Functional Expression of Transport Activity.
Isolation of
X. laevis oocytes was performed as described elsewhere
(Sekine et al., 1997
). Stage V and VI defolliculated oocytes were
selected throughout this experiment. To remove the follicular layer
from X. laevis oocytes, collagenase A (Roche Applied
Science, Mannheim, Germany) was used at a final concentration of
2.0 mg/ml in OR2 solution (83 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 5 mM HEPES, pH 7.5) and slowly shaken for
3 h at room temperature. The isolated cDNA, mOAT2, was linearized
with BamHI, and the capped cRNA was transcribed in vitro by
T7 RNA polymerase (Sekine et al., 1997
). Defolliculated oocytes were
microinjected with 10 ng of in vitro transcribed cRNA and incubated for
3 days in a modified Barth's solution containing 50 µg/ml gentamicin
at 18°C. Uptake experiments of radiolabeled substrates, as indicated
in each experiment, were performed in ND 96 solution (96 mM NaCl, 2 mM
KCl, 1.8 mM CaCl2, 1 mM
MgCl2, 5 mM HEPES, pH 7.4) at room temperature.
Oocytes were incubated in 450 µl of the same solution containing
radiolabeled substrates for 1 h at room temperature. The uptake
was terminated by the addition of 2 ml of ice-cold ND 96 solution, and
the oocytes were washed with the same solution at least five times. The
oocytes were solubilized with 10% SDS, and accumulated radioactivity
was determined by a liquid scintillation counter. The experiments were
repeated with oocytes from at least five frogs.
Kinetic Study. Concentration-dependent uptake experiments of PGE2 and glutarate via mOAT2 were performed with each compound at a final concentration range of 1, 5, 10, 25, and 50 nM and 1, 2, 5, 10, 50, and 100 µM, respectively. The compounds were incubated with expressing mOAT2 oocytes for 1 h at room temperature, stopped with ice-cold ND96 solution and washed five times as described above. Individual oocytes were transferred to scintillation vials and dissolved in 250 µl of 10% SDS. A scintillation cocktail was added, and radioactivity was counted. Counts in control uninjected oocytes were subtracted from the counts in cRNA-injected oocytes. Data are presented as mean ± S.E.M., except for kinetic constants, for which the error represents the error of the fit. Km indicates the Michaelis-Menten constant (nano- or micromolar).
Inhibition Study. For the inhibition experiments, oocytes expressing mOAT2 were incubated for 1 h in ND96 solution containing 5 µM [14C]glutarate in the presence or absence of various inhibitors at a final concentration of 1 mM, except for bromosulfophthalein (BSP) (250 µM). Cimetidine, indocyanine green (ICG), cefoperazone, enalapril, oxaloacetate, and erythromycin were directly dissolved in ND96 solution from stock solutions. These stock solutions of the inhibitors were prepared in dimethyl sulfoxide and diluted to a final concentration as described above. The final concentration of dimethyl sulfoxide in the assay medium did not exceed 1.0%.
Statistical Analysis. Kinetic data from experiments measuring the uptake of radiolabeled substrates were fit to the Michaelis-Menten equation by nonlinear least-squares regression analysis with standard errors derived from these curves. Comparisons of data measuring initial rates of uptake of radiolabeled substrates in the presence and absence of inhibitors were performed by the unpaired Student's t test.
| |
Results |
|---|
|
|
|---|
Cloning of mOAT2.
A nondirectional cDNA library of mouse
kidney was screened using a full-length rOAT2 cDNA as a probe. We
finally purified seven positive plaques. mOAT2 has a single open
reading frame of 1623 bp encoding a 540-amino acid sequence
(GenBank/EBI, AB069965) (Fig. 1).
Kyte-Doolittle hydropathy analysis with a window size of 19 predicts
that mOAT2 has 12 putative transmembrane domains. There are three
consensus sequences for N-glycosylation sites (Asn57, Asn91, and
Asn356) that are predicted to be in the first
hydrophilic loop and between the seventh and eighth transmembrane
domains in this protein. The sequence also contains six potential
protein kinase C-dependent phosphorylation sites
(Ser164, Thr198,
Ser254, Ser279,
Ser327, and Thr513) located
in intracellular loops. The amino acid sequence alignments of mOAT2
compared with rOAT2 is also shown in Fig. 1. The two sequences are 88%
identical. The amino acid sequence of mOAT2 is also 41% identical to
rOAT1 (Sekine et al., 1997
), 40% for mOAT1 (NKT) (Lopez-Nieto et al.,
1997
), 42% for hOAT1 (Hosoyamada et al., 1999
), 40% for rOAT3
(Kusuhara et al., 1999
), 41% for mOAT3 (Roct) (Brady et al., 1999
),
39% for hOAT3 (Cha et al., 2001
) and 38% for hOAT4 (Cha et al.,
2000
). While this study was being conducted, a sequence from the mouse
kidney with an unknown function was submitted to GenBank (BC013474).
The nucleotide sequence of mOAT2 is 99% identical to that of this gene
(BC013474) except one base change (G at position 136 to A) resulting in
the change of an amino acid (Ala46 to Thr).
|
Tissue Distribution of mOAT2 mRNA.
We have found that rOAT1,
rOAT3, hOAT3, and hOAT4 mRNAs are expressed predominantly in the kidney
(Sekine et al., 1997
; Kusuhara et al., 1999
; Cha et al., 2000
, 2001
).
In contrast, rOAT2 mRNA was strongly expressed in the liver and
relatively weakly expressed in the kidney (Simonson et al., 1994
;
Sekine et al., 1998
). Thus, the expression level of individual OAT
isoforms depends on the organ in which they are found. We subsequently
examined, based on these findings, the tissue distribution of mRNA
coding for mOAT2. Northern blot analysis of the mOAT2 revealed that a
single mRNA of 2.4 kb is abundant in the male mouse kidney and faintly expressed in the liver (Fig. 2A).
Hybridization signals could not be detected in mRNA isolated from other
tissues, such as the skeletal muscle, testis, pancreas, heart, brain,
lung, and eye. Thus, the expression of this gene is tissue-specific.
The result indicates that there exists a species-related differential
distribution of the OAT2 gene expression. The result
of Northern blot analysis regarding sex differences of the
mOAT2 gene is shown in Fig. 2B. The mOAT2 mRNA was clearly
expressed in the liver of female mice but weakly expressed in male mice
(Fig. 2B). No gender-related differential gene expression of mOAT2 was
detected in other tissues, such as skeletal muscle, testis, pancreas,
heart, brain, lung, and eye (data not shown). Taken together, our
results indicate that there exists a sex- and species-related
differential expression of OAT2 isoform in rodents.
|
Chromosomal Localization of mOAT2.
To determine the
chromosomal localization of the mOAT2 gene, we subsequently
performed a FISH analysis. Under the conditions described in the
experimental procedures, FISH detection efficiency was 88% using mOAT2
cDNA as a probe (among 100 checked mitotic figures, 88 of them showed
hybridization signals on one pair of chromosomes). Because the DAPI
banding was performed to identify the specific chromosome, the
assignment between signals from the probe and mouse chromosome 17 was
obtained. The detailed position was further determined based on a
summary from 10 photos (Fig. 3).
Therefore, this gene is mapped to chromosome 17C.
|
Functional Characterization of mOAT2.
Various endogenous and
exogenous organic anion substrates such as PAH, nonsteroidal
anti-inflammatory drugs, diuretics, angiotensin-converting enzyme
inhibitor, conjugated steroid hormones, and intermediates of the
tricarboxylic acid cycle (dicarboxylate) are transported by OAT1, -3, and -4 (Sekine et al., 1997
; Apiwattanakul et al., 1999
; Hosoyamada et
al., 1999
; Kusuhara et al., 1999
; Cha et al., 2000
, 2001
).
Liver-predominant rOAT2 mediates the transport of salicylate,
PGE2, MTX, acetylsalicylate, PAH, and
-ketoglutarate (Sekine et al., 1998
). Thus, all OAT isoforms are
known to be polyspecific organic anion transporters. We chose, based on
these findings, some of these organic anions to test substrate
specificity of mOAT2. X. laevis oocytes injected with mOAT2
cRNA were used for the transport characterization. As shown in Fig.
4, mOAT2 mediated the transport of
[14C]
-ketoglutarate,
[3H]MTX,
[3H]PGE2,
[14C]valproate,
[14C]glutarate,
[3H]OTA, [14C]PAH, and
[3H]allopurinol. We did not observe
mOAT2-mediated transport of [3H]estradiol
glucuronide, [3H]estrone sulfate,
[14C]indomethacin,
[14C]3'-azido-3'-deoxythymidine,
[14C]testosterone,
[14C]progesterone, and
[14C]androstenedione (data not shown).
Interestingly, mOAT2 also failed to transport
[14C]salicylate, despite the fact that it is a
good compound for rOAT2 (Fig. 4) (Sekine et al., 1998
). These findings
indicate that mOAT2 is a multispecific organic anion transporter with
some differences in substrate specificity compared with the rat
ortholog.
|
|
|
Inhibition Study.
To investigate further the substrate
specificity of mOAT2, we subsequently examined the inhibition of
mOAT2-mediated [14C]glutarate uptake by various
compounds. As illustrated in Fig. 7,
cis-inhibitory effects were
observed for structurally unrelated organic anions. The inhibition of
the mOAT2-mediated transport of [14C]glutarate
exhibited a rank order of erythromycin > BSP > cimetidine = ICG = enalapril > cefoperazone > oxaloacetate (Fig. 7). Although erythromycin did not inhibit the
rOAT2-mediated uptake of [14C]salicylate
(Sekine et al., 1998
), this compound proved to be the most potent
inhibitor for the mOAT2-mediated uptake of
[14C]glutarate. These results suggest that
substrate specificity of mOAT2 is different from that of rOAT2.
|
| |
Discussion |
|---|
|
|
|---|
In the present study, we report the isolation and functional
characterization of multispecific OAT2 from a mouse kidney cDNA library. mOAT2 has an open reading frame encoding a 540 amino acid
protein, and the hydropathy plot of mOAT2 using the algorithm of
Kyte-Doolittle predicts 12 putative membrane-spanning domains. The
Slc22a7 gene, coding for mOAT2, is located on chromosome
17C. The mOAT2 gene was abundantly expressed in the male
mouse kidney but faintly expressed in the liver, whereas the expression
level of this gene was detected in almost equal amounts in the female liver and kidney. Moreover, we found that the expression of mOAT2 in
the liver of rats and mice is quite different, indicating that there is
a species- and sex-dependent expression of OAT2. Functional experiments
have revealed that mOAT2 mediates the uptake of various organic anions
such as
-ketoglutarate, MTX, PGE2, valproate, glutarate, OTA, PAH, and allopurinol, but not salicylate, in a sodium-independent manner. The concentration dependence of the uptake
of glutarate and PGE2 via mOAT2 was saturable
with Km values of 15.8 ± 3.2 µM and 5.2 ± 0.5 nM for glutarate and
PGE2, respectively. The mOAT2-mediated transport
of glutarate was strongly inhibited by various organic compounds,
erythromycin in particular. All of these findings together with
previous reports (Sekine et al., 1997
; Kusuhara et al., 1999
; Cha et
al., 2000
, 2001
) suggest that mOAT2 is a multispecific organic anion transporter.
To date, at least five distinct OAT isoforms have been identified and
their transport characteristics have already been characterized, except
for OAT5 (Sekine et al., 1997
, 1998
; Kusuhara et al., 1999
; Cha et al.,
2000
; Sun et al., 2001
). These isoforms are multispecific transporters
that interact with a wide range of organic anions such as nonsteroidal
anti-inflammatory drugs, diuretics, and
-lactam antibiotics (Sekine
et al., 1997
, 1998
; Kusuhara et al., 1999
; Cha et al., 2000
; Sun et
al., 2001
). Of the prototype substrate for individual OAT isoforms, we
have shown that rOAT1 mediates the high-affinity transport of PAH
(Sekine et al., 1997
). Sulfate-conjugated steroids (estrone sulfate and
dehydroepiandrostenedione sulfate) and salicylate are preferred
substrates of hOAT4 and rOAT2, respectively, although a very low rate
of uptake of PAH via OAT2/OAT4 has also been observed (Sekine et al.,
1998
; Cha et al., 2000
). OAT3, as well as OAT1, is predominantly
expressed in the kidney and mediates the transport of PAH (Cha et al.,
2001
). Thus, substrates for the individual OAT isoforms partially
overlap, but it seems to be the same compound in different species. For
example, hOAT1 also mediated the transport of PAH as well as rat and
mouse OAT1 (Hosoyamada et al., 1999
; Pavlova et al., 2000
). However, we
did not observe the mOAT2-mediated uptake of salicylate, despite the fact that salicylate is a good substrate of rOAT2 (Sekine et al., 1998
). Our results indicate that the mOAT2 transporter has somewhat different substrate specificity than that of rOAT2.
Based on the transport experiment mediated by mOAT2, we subsequently
studied the inhibitory effect of the mOAT2-mediated uptake by various
organic anions to obtain more detailed substrate selectivity. Because
the chemical structure between glutarate and
-ketoglutarate is very
similar, we chose glutarate for this experiment. The transport of
glutarate mediated by mOAT2 interacted with structurally unrelated compounds such as BSP, ICG, and cefoperazone as observed in rOAT2 (Sekine et al., 1998
). Specifically, we observed that erythromycin is
the most potent inhibitor in oocytes expressing mOAT2 compared with
rOAT2 indicating that these closely-related proteins have differences
in functions. At present, however, we have no definite explanations for
the differential functions between rOAT2 and mOAT2; it is possible that
the binding interaction between the substrate and the carrier may vary
because the molecular size and lipophilicity of salicylate is larger
than that of glutarate. Comparison of the transport profile of
glutarate and salicylate mediated by the OAT2 isoform would also lead
to further information of substrate specificity. In this respect,
further precise studies (i.e., structure-function analysis) are needed
to determine whether erythromycin is able to inhibit transport of
glutarate uptake mediated by rOAT2.
It has been reported that rOAT1 and rOAT3 are predominantly expressed
in the kidney (Sekine et al., 1997
; Kusuhara et al., 1999
), whereas
rOAT2 (NLT) is abundantly expressed in the liver (Simonson et al.,
1994
; Sekine et al., 1998
). OAT4 is also represented in the human
placenta as well as in the kidney (Cha et al., 2000
). Thus, the
expression level of the individual OAT isoform depends on the organ in
which the isoform is found. In the present study, we found that mOAT2
mRNA in male mice is predominantly expressed in the kidney but faintly
expressed in the liver, whereas this gene is markedly expressed in the
female liver and kidney. On this basis, we examined whether there
exists such a sex-related differential expression of mOAT1
(NKT) and mOAT3 (Roct) genes. We observed that they are only
kidney and no sex differences (data not shown), indicating that only
mOAT2 shows a sex-related differential distribution among these OAT
isoforms. Although a previous study showed a rather broad distribution
of the mOAT2 (NLT) isoform in mice (Pavlova et al., 2000
), the study
was done using human cDNA encoding part of the rOAT2 probe which could
produce nonspecific hybridization signals. From all of these findings,
we concluded that only the mOAT2 isoform is expressed with sex
dependence in the liver. Whether such a sex-dependent expression of
mOAT2 could be observed at protein levels needs further study.
A similar observation of the sex-related differential gene expression
in the liver and/or kidney has been reported. For example, the
male-liver specific cytochrome P450 species CYP2C11 is expressed only in the liver, whereas CYP2C12 (female liver-specific) is detected
only in females (Gonzalez, 1989
). These sex-specific cytochrome P450
isoforms can be regulated by the secretion pattern of growth hormones
(Kamataki et al., 1983
; Yamazoe et al., 1989
; Imaoka et al., 1992
).
Taking these facts into consideration, observed sex differences in the
expression of the OAT2 isoform of the liver may be regulated by sex
steroids, such as testosterone, resulting in the sex-dependent
expression of the OAT2 isoform. Taken together, these data lead us to
conclude that there is a sex- and species-related differential
expression of OAT2 mRNA in rodents. For a comprehensive understanding
of the physiological role of the OAT2 isoform, investigation of the
contribution of OAT2 in the liver is required from a pharmacological and pharmacokinetic point of view. It would be of interest to elucidate
whether there is such a sex-associated differential distribution of the
OAT isoform in other species such as the rat and the human.
In conclusion, we describe the molecular cloning, functional characterization, and sex-related differential gene expression of OAT2 in mice. We found that the expression level of mOAT2 mRNA in the liver and kidney of male mice is different from that of female mice. Uptake experiments have revealed that mOAT2 mediates the transport of various kinds of structurally unrelated drugs and chemicals in a sodium-independent manner. The mOAT2-mediated transport of glutarate was strongly inhibited by the addition of erythromycin in vitro. The mOAT2 transporter has somewhat different substrate specificity than rOAT2. Our results explain the sex-associated differences in pharmacokinetics and toxicokinetics of drugs and chemicals in vivo and indicate that rats and mice are good tools for investigation of drug development and construction of an organ and/or a transporter targeting drug-delivery system. Hence, attention should be paid to the sex and species of experimental animals when testing anionic drugs and chemicals in pharmacokinetic and toxicokinetic studies.
| |
Acknowledgments |
|---|
We express special thanks to Dr. Ana M. Pajor (Department of Physiology and Biophysics, The University of Texas Medical Branch at Galveston, Galveston, TX) for critical reading of this manuscript. We also gratefully acknowledge E. Tabuchi for skillful assistance in part of this study.
| |
Footnotes |
|---|
Received December 28, 2001; Accepted March 20, 2002
1 Present address: Department of Physiology and Biophysics, The University of Texas Medical Branch at Galveston, Galveston, Texas 77555-1031.
This work was supported in part by Grants-in-Aid from the Nakatomi Foundation (H13). Y.K. and N.O. contributed equally to this work.
Address correspondence to: Toshinori Yamamoto, Ph.D. Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555. E-mail: yamagen{at}pharm.showa-u.ac.jp
| |
Abbreviations |
|---|
OAT, organic anion transporter;
rOAT, rat
organic anion transporter;
mOAT, mouse organic anion transporter;
hOAT, human organic anion transporter;
PG, prostaglandin;
NLT, novel
liver-specific transport protein;
MTX, methotrexate;
PAH, p-aminohippuric acid;
Roct, reduced in oc
transporter;
OTA, ochratoxin A;
dCTP, deoxycytidine
[5'-
-32P]triphosphate;
SSC, standard saline citrate;
MES, 2-morpholinoethanesulfonic acid;
GTC, guanidinium thiocyanate;
FISH, fluorescent in situ hybridization;
DAPI, 4,6-diamino-2-phenylindole;
BSP, bromosulfophthalein;
ICG, indocyanine
green;
bp, base pair(s);
kb, kilobase(s).
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Baltes, M. Fedrowitz, C. L. Tortos, H. Potschka, and W. Loscher Valproic Acid Is Not a Substrate for P-glycoprotein or Multidrug Resistance Proteins 1 and 2 in a Number of in Vitro and in Vivo Transport Assays J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 331 - 343. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ljubojevic, D. Balen, D. Breljak, M. Kusan, N. Anzai, A. Bahn, G. Burckhardt, and I. Sabolic Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones Am J Physiol Renal Physiol, January 1, 2007; 292(1): F361 - F372. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Schnabolk, G. L. Youngblood, and D. H. Sweet Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20) Am J Physiol Renal Physiol, August 1, 2006; 291(2): F314 - F321. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Eraly, V. Vallon, D. A. Vaughn, J. A. Gangoiti, K. Richter, M. Nagle, J. C. Monte, T. Rieg, D. M. Truong, J. M. Long, et al. Decreased Renal Organic Anion Secretion and Plasma Accumulation of Endogenous Organic Anions in OAT1 Knock-out Mice J. Biol. Chem., February 24, 2006; 281(8): 5072 - 5083. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sekine, H. Miyazaki, and H. Endou Molecular physiology of renal organic anion transporters Am J Physiol Renal Physiol, February 1, 2006; 290(2): F251 - F261. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kobayashi, A. Shibusawa, H. Saito, N. Ohshiro, M. Ohbayashi, N. Kohyama, and T. Yamamoto Isolation and Functional Characterization of a Novel Organic Solute Carrier Protein, hOSCP1 J. Biol. Chem., September 16, 2005; 280(37): 32332 - 32339. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C Whitley, D. H. Sweet, and T. Walle THE DIETARY POLYPHENOL ELLAGIC ACID IS A POTENT INHIBITOR OF hOAT1 Drug Metab. Dispos., August 1, 2005; 33(8): 1097 - 1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Kobayashi, R. Sakai, N. Ohshiro, M. Ohbayashi, N. Kohyama, and T. Yamamoto POSSIBLE INVOLVEMENT OF ORGANIC ANION TRANSPORTER 2 ON THE INTERACTION OF THEOPHYLLINE WITH ERYTHROMYCIN IN THE HUMAN LIVER Drug Metab. Dispos., May 1, 2005; 33(5): 619 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Youngblood and D. H. Sweet Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney Am J Physiol Renal Physiol, August 1, 2004; 287(2): F236 - F244. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Eraly, J. C. Monte, and S. K. Nigam Novel slc22 transporter homologs in fly, worm, and human clarify the phylogeny of organic anion and cation transporters Physiol Genomics, June 17, 2004; 18(1): 12 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Eraly, K. T. Bush, R. V. Sampogna, V. Bhatnagar, and S. K. Nigam The Molecular Pharmacology of Organic Anion Transporters: from DNA to FDA? Mol. Pharmacol., March 1, 2004; 65(3): 479 - 487. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||